title: Synthesis and biological characterisation of 18F-SIG343 and 18F-SIG353, novel and high selectivity σ2 radiotracers, for tumour imaging properties.
abstract: BACKGROUND
  Sigma2 (σ2) receptors are highly expressed in cancer cell lines and in tumours. Two novel selective 18F-phthalimido σ2 ligands, 18F-SIG343 and 18F-SIG353, were prepared and characterised for their potential tumour imaging properties.
  
  
  METHODS
  Preparation of 18F-SIG343 and 18F-SIG353 was achieved via nucleophilic substitution of their respective nitro precursors. In vitro studies including radioreceptor binding assays in the rat brain membrane and cell uptake studies in the A375 cell line were performed. In vivo studies were carried out in mice bearing A375 tumours including positron emission tomography (PET) imaging, biodistribution, blocking and metabolite studies.
  
  
  RESULTS
  In vitro studies showed that SIG343 and SIG353 displayed excellent affinity and selectivity for σ2 receptors (Ki(σ2) = 8 and 3 nM, σ2:σ1 = 200- and 110-fold, respectively). The σ2 selectivity of 18F-SIG343 was further confirmed by blocking studies in A375 cells, however, not noted for 18F-SIG353. Biodistribution studies showed that both radiotracers had similar characteristics including moderately high tumour uptake (4%ID/g to 5%ID/g); low bone uptake (3%ID/g to 4%ID/g); and high tumour-to-muscle uptake ratios (four- to sevenfold) up to 120 min. Although radiotracer uptake in organs known to express σ receptors was significantly blocked by pre-injection of competing σ ligands, the blocking effect was not observed in the tumour. PET imaging studies indicated major radioactive localisation in the chest cavity for both ligands, with approximately 1%ID/g uptake in the tumour at 120 min. Metabolite studies showed that the original radiotracers remained unchanged 65% to 80% in the tumour up to 120 min.
  
  
  CONCLUSIONS
  The lead ligands showed promising in vitro and in vivo characteristics. However, PET imaging indicated low tumour-to-background ratios. Furthermore, we were unable to demonstrate that uptake in the A375 tumour was σ2-specific. 18F-SIG343 and 18F-SIG343 do not display ideal properties for imaging the σ2 receptor in the A375 tumour model. However, since the radiotracers show promising in vitro and in vivo characteristics, longer scans using appropriate half-life isotopes and alternative tumour models will be carried out in future studies to fully validate the imaging characteristics of these radiotracers.
authors: LifeSciences, ANSTO, Locked Bag 2001, Kirrawee, New South Wales 2232, Australia. vu.nguyen@ansto.gov.au.
authors: Vu H
authors: VH
authors: Nguyen
authors: Tien
authors: T
authors: Pham
authors: Chris
authors: C
authors: Fookes
authors: Paula
authors: P
authors: Berghofer
authors: Ivan
authors: I
authors: Greguric
authors: Andrew
authors: A
authors: Arthur
authors: Filomena
authors: F
authors: Mattner
authors: Gita
authors: G
authors: Rahardjo
authors: Emma
authors: E
authors: Davis
authors: Nicholas
authors: N
authors: Howell
authors: Marie-Claude
authors: MC
authors: Gregoire
authors: Andrew
authors: A
authors: Katsifis
authors: Rachael
authors: R
authors: Shepherd